Post by Swiss TPH

Last week, Novartis and Medicines for Malaria Venture (MMV) announced that their candidate drug GanLum (ganaplacide / lumefantrine, or KLU156) met its primary endpoint in a Phase III trial across 12 African countries. As the first non-artemisinin-based combination to reach this stage in more than 20 years GanLum has high potential to combat antimalarial resistance. Swiss TPH contributed to the development of the drug from early scientific work to clinical validation.